Flood of warning letters follows DTC ad clampdown

Описание: In today’s headlines – 17 September:

The FDA has lost no time following through on its plan to tighten up DTC advertising of medicines, sending out dozens of untitled and warning letters.

A $30bn investment drive by GSK in the US includes a new facility in Pennsylvania, and follows a string of abandoned projects by pharma groups in the UK.

AstraZeneca has abandoned Fasenra development in COPD, but there is better news for the company with a new version of lupus drug Saphnelo.

Eli Lilly is preparing to file for approval of its oral weight-loss drug orforglipron before year-end, but not all are convinced by the data.

Digital health tech for opioid use disorder can be as effective as regular care, but it doesn't expand access and may increase the cost of care.

Subscribe to ‪@Pharmaphorum‬ for daily news updates and check out www.pharmaphorum.com for more insights and analysis.

#news #pharma #pharmanews #pharmainnovation #pharmaindustry #lifesciences #biotechnews #biopharma #drugdevelopment #drugdiscovery #fda #dtcmarketing #dtcadvertising #medicines #gsk #pharmamanufacturing #astrazeneca #copd #elililly #glp1medications #weightlossmedication #digitalhealth #opioidtreatment #opioidusedisorder #accesstohealthcare #ushealthcare #ukhealthcare